Abbott Laboratories Q1 Earnings Call Highlights
Abbott Laboratories reported Q1 2026 adjusted EPS of $1.15, in line with expectations, but faced a 10% decline in rapid/molecular diagnostics due to a weaker respiratory season. The company completed its acquisition of Exact Sciences, which is expected to add $3 billion in incremental sales in 2026 but cause near-term EPS dilution.
Topics: Acquisition Earnings Financial Performance Stock Outlook